DANVERS, Mass. – Nov. 27, 2023 – Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been enrolled in the landmark RECOVER IV randomized controlled trial (RCT).
Abiomed announces enrollment of first patient in landmark RECOVER IV trial for AMI cardiogenic shock
Abiomed, part of Johnson & Johnson MedTech, announces the first patient in the world has been enrolled in the landmark RECOVER IV randomized controlled trial (RCT). The on-label, two-arm trial will ...
Cardiogenic shock care extends beyond rapid decision-making at the bedside, a new review asserts. Clearer understanding of shock’s diversity and how best to tackle its acute manifestations, as well as ...
DANVERS, Mass.--(BUSINESS WIRE)--Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI. The ...
A large multicenter study provides further evidence supporting the rationale for multidisciplinary teams for cardiogenic shock, one of the most lethal diseases in cardiovascular medicine. The analysis ...
The number of patients with cardiogenic shock across the country has increased and it is clear that timely decision-making and intervention are critical to survival. Nationwide, half of all patients ...
More than a quarter of patients with early-stage cardiogenic shock had to be transferred to a higher level of care, progressed to a worse stage of shock, or died, according to a study in six US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback